131 related articles for article (PubMed ID: 36047190)
1. A Reactive Metabolite of Clozapine Induces Hematopoietic Toxicity in HL-60 Cells Undergoing Granulocytic Differentiation through Its Effect on Glutathione Metabolism.
Torii-Goto A; Yoshimi A; Tashiro Y; Ukigai M; Matsumoto A; Ozaki N; Noda Y
Biol Pharm Bull; 2022; 45(9):1232-1237. PubMed ID: 36047190
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the histamine H4 receptor in clozapine-induced hematopoietic toxicity: Vulnerability under granulocytic differentiation of HL-60 cells.
Goto A; Mouri A; Nagai T; Yoshimi A; Ukigai M; Tsubai T; Hida H; Ozaki N; Noda Y
Toxicol Appl Pharmacol; 2016 Sep; 306():8-16. PubMed ID: 27368152
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis.
Williams DP; Pirmohamed M; Naisbitt DJ; Maggs JL; Park BK
J Pharmacol Exp Ther; 1997 Dec; 283(3):1375-82. PubMed ID: 9400013
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes.
Gardner I; Zahid N; MacCrimmon D; Uetrecht JP
Mol Pharmacol; 1998 Jun; 53(6):991-8. PubMed ID: 9614200
[TBL] [Abstract][Full Text] [Related]
5. Potential role of a quetiapine metabolite in quetiapine-induced neutropenia and agranulocytosis.
Li X; Cameron MD
Chem Res Toxicol; 2012 May; 25(5):1004-11. PubMed ID: 22506851
[TBL] [Abstract][Full Text] [Related]
6. Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis.
Iverson S; Zahid N; Uetrecht JP
Chem Biol Interact; 2002 Nov; 142(1-2):175-99. PubMed ID: 12399162
[TBL] [Abstract][Full Text] [Related]
7. Structural features associated with reactive metabolite formation in clozapine analogues.
Uetrecht J; Zahid N; Tehim A; Fu JM; Rakhit S
Chem Biol Interact; 1997 May; 104(2-3):117-29. PubMed ID: 9212779
[TBL] [Abstract][Full Text] [Related]
8. Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis.
Pereira A; Dean B
Biochem Pharmacol; 2006 Sep; 72(6):783-93. PubMed ID: 16844094
[TBL] [Abstract][Full Text] [Related]
9. Possible nonimmunological toxicological mechanisms of vesnarinone-associated agranulocytosis in HL-60 cells: role of reduced glutathione as cytotoxic defense.
Koga T; Sahara Y; Ohtani T; Yosuke K; Umehara K
J Toxicol Sci; 2024; 49(3):95-103. PubMed ID: 38432956
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis.
Uetrecht JP
Drug Saf; 1992; 7 Suppl 1():51-6. PubMed ID: 1503678
[TBL] [Abstract][Full Text] [Related]
11. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine.
Williams DP; Pirmohamed M; Naisbitt DJ; Uetrecht JP; Park BK
Mol Pharmacol; 2000 Jul; 58(1):207-16. PubMed ID: 10860943
[TBL] [Abstract][Full Text] [Related]
12. Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis.
Ng W; Kennar R; Uetrecht J
Chem Res Toxicol; 2014 Jul; 27(7):1104-8. PubMed ID: 24968069
[TBL] [Abstract][Full Text] [Related]
13. Effect of clozapine on neutrophil kinetics in rabbits.
Iverson S; Kautiainen A; Ip J; Uetrecht JP
Chem Res Toxicol; 2010 Jul; 23(7):1184-91. PubMed ID: 20553052
[TBL] [Abstract][Full Text] [Related]
14. Human neutrophils show decreased survival upon long-term exposure to clozapine.
Goto A; Yoshimi A; Nagai T; Ukigai M; Mouri A; Ozaki N; Noda Y
Hum Psychopharmacol; 2017 Nov; 32(6):. PubMed ID: 28913970
[TBL] [Abstract][Full Text] [Related]
15. Testing the hypothesis that selenium deficiency is a risk factor for clozapine-induced agranulocytosis in rats.
Ip J; Uetrecht JP
Chem Res Toxicol; 2008 Apr; 21(4):874-8. PubMed ID: 18380444
[TBL] [Abstract][Full Text] [Related]
16. The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis.
Tschen AC; Rieder MJ; Oyewumi LK; Freeman DJ
Clin Pharmacol Ther; 1999 May; 65(5):526-32. PubMed ID: 10340918
[TBL] [Abstract][Full Text] [Related]
17. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man.
Maggs JL; Williams D; Pirmohamed M; Park BK
J Pharmacol Exp Ther; 1995 Dec; 275(3):1463-75. PubMed ID: 8531117
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo.
Gardner I; Leeder JS; Chin T; Zahid N; Uetrecht JP
Mol Pharmacol; 1998 Jun; 53(6):999-1008. PubMed ID: 9614201
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of clozapine-induced agranulocytosis : current status of research and implications for drug development.
Pirmohamed M; Park K
CNS Drugs; 1997 Feb; 7(2):139-58. PubMed ID: 23338132
[TBL] [Abstract][Full Text] [Related]
20. Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis.
Fischer V; Haar JA; Greiner L; Lloyd RV; Mason RP
Mol Pharmacol; 1991 Nov; 40(5):846-53. PubMed ID: 1658615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
